Pharmacology and treatments

Drugs and the Future

Volumn , Issue , 2007, Pages 169-208

  Iversen, Leslie ^a   Morris, Kelly ^b   Nutt, David ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880287559     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370624-9/50009-8     Document Type: Chapter

References (282)

1. Addolorato G., Ancona C., Capristo E., Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol 2003, 16:207-214.
2. Aghajanian G.K., Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 1999, 21:S16-S23.
3. Agrawal A., Neale M.C., Prescott C.A., Kendler K.S. Cannabis and other illicit drugs: comorbid use and abuse/dependence in males and females. Behav Genet 2004, 34(3):217-228.
4. Altman J., Everitt B.J., Glautier S., et al. The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacology 1996, 125:285-345.
5. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, APA, Washington DC. 4th edition (text revision).
6. Amos A., Wiltshire S., Bostock Y., Haw S., McNeill A. You can't go without a fag .. you need it for your hash-a qualitative exploration of smoking, cannabis and young people. Addiction, Jan. 2004, 99(1):77-81.
7. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306(5697):879-881.
8. Ashton H., Young A.H. GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol 2003, 17(2):174-178.
9. Assadi S.M., Radgoodarzi R., Ahmadi-Abhari S.A. Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial. BMC psychiatry 2003, 3(1):16.
10. Barker M.J., Greenwood K.M., Jackson M., Crowe S.F. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol, Apr. 2004, 19(3):437-454.
11. Bartoletti M., Gubellini C., Ricci F., Gaiardi M. The GABAB agonist baclofen blocks the expression of sensitisation to the locomotor stimulant effect of amphetamine. Behav Pharmacol 2004, 15(56):397-401.
12. Baumann M.H., Rothman R.B., Pablo J.P., Mash D.C. In vivo neurobiological effects of ibogaine and its o-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 2001, 297:531-539.
13. Baumann M.H., Phillips J.M., Ayestas M.A., Ali S.F., Rice K.C., Rothman R.B. Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence. Ann NY Acad Sci 2002, 965:92-108.
14. Bearn J., Gossop M., Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 1998, (3):227-232.
15. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2004, 20 Oct. Epub ahead of print.
16. Beswick T., Best D., Bearn J., Gossop M., Rees S., Strang J. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial. Am J Addict 2003, 12(4):295-305.
17. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 2003, 64(Suppl II):3-8.
18. Blakemore C. A scientifically based scale of harm for all social drugs. Proceedings of seminar III: alcohol and other recreational drugs 2003, Beckley Foundation, Oxford.
19. Bolanos C.A., Barrot M., Bertob O., Wallace-Black D., Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 2003, 54:1317-1329.
20. Bonci A., Bernardi G., Grillner P., Mercuri N.B. The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction?. Trends Pharm Sci 2003, 24(4):172-177.
21. Bono G., Sinforiani E., Merlo P., Belloni G., Soldati M., Gelso E. Alcoholic abstinence syndrome: short-term treatment with metadoxine. Int J Clin Pharmacol Res 1991, 11:35-40.
22. Boot B.P., McGregor I.S., Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000, 355:1818-1821.
23. Boyle P., Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005, Epub 15 February. doi:10.1093/annonc/mdi098.
24. Brandon C.L., Marinelli M., White F.J. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry 2003, 54:1338-1344.
25. Breese G.R., Knapp D.J., Overstreet D.H. Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT1A receptor agonist. Neuropsychopharmacology 2004, 29(3):470-482.
26. Therapeutic uses of cannabis 1997, British Medical Association, Harwood, Netherlands.
27. Broadbent J., Harless W.E. Differential effects of GABA (A) and GABA (B) agonists on sensitization to the locomotor stimulant effects of ethanol in DBA/2 J mice. Psychopharmacology 1999, 141(2):197-205.
28. Brodie J.D., Figueroa E., Dewey S.L. Treating cocaine addiction: from preclinical to clinical trial experience with <>-vinyl GABA. Synapse 2003, 50:261-265.
29. Budygin E.A., Brodie M.S., Sotnikova T.D., et al. Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proc Natl Acad Sci USA 2004, 101(20):7781-7786.
30. Bunce C.J., Loudon P.T., Akers C., Dobson J., Wood D.M. Development of vaccines to help treat drug dependence. Curr Opin Mol Ther 2003, 5(1):58-63.
31. Buntwal N., Bearn J., Gossop M., Strang J. Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug Alcohol Depend 2000, 59(2):183-188.
32. Burstein S.H., Karst M., Schneider U., Zurier R.B. Ajulemic acid: A novel cannabinoid produces analgesia without a 'high'. Life Sci 2004, 75:1513-1522.
33. Bush W., Roberts M., Trace M. Upheavals in the Australian drug market: heroin drought, stimulant flood 2004, Beckley Foundation, Oxford.
34. Cadet J.L., Jayanthi S., Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 2003, 17:1775-1788.
35. Cain C.K., Blouin A.M., Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 2004, 11(2):179-187.
36. Camarini R., Frussa-Filho R., Monteiro M.G., Calil H.M. MK-801 blocks the development of behavioral sensitization to the ethanol. Alcohol Clin Exp Res 2000, 24(3):285-290.
37. Campiani G., Butini S., Trotta F., et al. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 2003, 46(18):3822-3839.
38. Capps B., Campbell A., Ashcroft R. Foresight state of science review-ethical aspects of developments on neuroscience and drug addiction 2005, Department of Trade and Industry, London.
39. Cardinal R.N., Winstanley C.A., Robbins T.W., Everitt B.J. Limbic corticostriatal systems and delayed reinforcement. Ann NY Acad Sci 2004, 1021:33-50.
40. Carlezon W.A., Mague S.D., Anderson S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 2003, 54:1330-1337.
41. Carlini E.A. Plants and the central nervous system. Pharmacol Biochem Behav 2003, 75:501-512.
42. Carmen B., Angeles M., Ana M., Maria A.J. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004, 99:811-828.
43. Carreno J.E., Alvarez C.E., Narciso G.I., Bascaran M.T., Diaz M., Bobes J. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol 2003, 8(4):429-438.
44. Carrera M.R.A., Kaufmann G.F., Mee J.M., Meijler M., Koob G.F., Janda K.D. Treating cocaine addiction with viruses. Proc Natl Acad Sci USA 2004, 101:10416-10421. Epub 28 June. doi: 10.1073/pnas.0403795101.
45. Check E. The ups and downs of ecstasy. Nature 2004, 429:126-128.
46. Chichewicz D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004, 74:1317-1324.
47. Choi S., Silverman R.B. Inactivation and inhibition of gamma-aminobutyric acid aminotransferase by conformationally restricted vigabatrin analogues. J Med Chem 2002, 45(20):4531-4539.
48. Choi D.S., Wang D., Dadgar J., Chang W.S., Messing R.O. Conditional rescue of protein kinase C epsilon regulates ethanol preference and hypnotic sensitivity in adult mice. J Neurosci 2002, 22(22):9905.
49. Choi D.S., Cascini M.G., Mailliard W., et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004, 18 July. Epub ahead of print. doi:10.1038/nn1288.
50. Cole J.C., Sumnall H.R. Altered states: the clinical effects of Ecstasy. Pharm Ther 2003, 98:35-58.
51. Condon J., Smith N. Prevalence of drug use: key findings from the 2002/2003. British Crime Survey. Findings 229 2003, Home Office, London.
52. Connor T.J. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology 2004, 111:357-367.
53. Contet C., Kieffer B.L., Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 2004, 14:370-378.
54. Cook C.J. Stress induces CRF release in the paraventricular nucleus, and both CRF and GABA release in the amygdala. Physiol Behav 2004, 82(4):751-762.
55. Cousins M.S., Roberts D.C., de Wit H. GABA (B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002, 65(3):209-220.
56. Cowen M.S., Chen F., Lawrence A.J. Neuropeptides: implications for alcoholism. J Neurochem 2004, 89(2):273-285.
57. Cryan J.F., Gasparini F., van Heeke G., Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond buproprion. Drug Discov Today 2003, 8(22):1025-1034.
58. Czoty P.W., Ginsburg B.C., Howell L.L. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 2002, 300(3):831-887.
59. d'Abbs P., Brady M. Other people, other drugs: the policy response to petrol sniffing among indigenous Australians. Drug Alcohol Rev 2004, 23(3):253-260.
60. Dalal S., Melrack R. Potentiation of opioid analgesia by psychostimulant drugs: a review. J Pain Symptom Manage 1998, 16:245-253.
61. De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addictive Behaviors 2004, 29:1325-1339.
62. Degenhardt L., Hall W., Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003, 71(1):37-48.
63. Degenhardt L., Hall W., Lynskey M. Exploring the association between cannabis use and depression. Addiction 2003, 98(11):1493-1504.
64. Department of Health. (2004) CMO update May: 8-9. http://www.dh.gov.uk/cmo/.
65. Dewey S.L., Brodie J.D., Gerasimov M., Horan B., Gardner E.L., Ashby C.R. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31(1):76-86.
66. Diaz Martinez M.C., Diaz Martinez A., Villamil Salcedo V., Cruz Fuentes C. Efficacy of metadoxine in the management of acute alcohol intoxication. J Int Med Res 2002, 30:44-51.
67. DiLeone R.J., Georgescu D., Nestler E.J. Lateral hypothalamic neuropeptides in reward and drug addiction. Life Sci 2003, 73(6):759-768.
68. Drugscope. How many people die from using drugs? http://www.drugscope.org.uk.
69. Drummond C., Curran V. Foresight state of science review-psychological treatments of substance abuse 2005, Department of Trade and Industry, London.
70. Dutta A.K., Zhang S., Kolhatkar R., Reith M.E.A. Dopamine transporter as target for drug development of cocaine dependence medications. Eur J Pharmacol 2003, 479:93-106.
71. Dwoskin L.P., Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 2002, 63(2):89-98.
72. Everitt B. Amphetamine and cocaine-mechanisms and hazards. Proceedings of seminar I: Drugs and the brain 2002, Beckley Foundation, Oxford.
73. Fadda P., Scherma M., Fresu A., Collu M., Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003, 50(1):1-6.
74. Faraone S.V., Wilens T. Does stimulant treatment lead to substance use disorders?. J Clin Psychiatry 2003, 64(Suppl 11):9-13.
75. Farber N.B., Olney J.W. Drugs of abuse that cause developing neurons to commit suicide. Developmental Brain Res 2003, 147:37-45.
76. Fattore L., Cossu G., Martellotta M.C., Deiana S., Fratta W. Baclofen antagonises intravenous self-administration of gamma-hydroxybutyric acid in mice. Neuroreport 2001, 12(10):2243-2246.
77. Fischer M., Barkley R.A. Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry 2003, 64(Suppl II):19-23.
78. Foster J., Brewer C., Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003, 8(2):211-217.
79. Fowler J.S., Logan J., Wang G.J., Volkow N.D. Monoamine oxidase and cigarette smoking. Neurotoxicology 2003, 24(1):75-82.
80. Frank M.J., O'Reilly R.C., Seeberger L.C. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science Express 2004, 4 Nov. doi: 10.1126/science. 1102941.
81. Franken I.H. Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(4):563-579.
82. Gable R.S. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004, 99:686-696.
83. Gal K., Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine selfadministration in rats. Brain Res Bull 2003, 61(6):595-601.
84. Garten S., Falkner R.V. Role of mentholated cigarettes in increased nicotine dependence and greater risk of tobacco-attributable disease. Prev Med 2004, 38:793-798.
85. George T.P., O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci Jan 2004, 25(1):42-48.
86. George T.P., Verrico C.D., Picciotto M.R., Roth R.H. Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharm Exp Ther 2000, 295:58-66.
87. Glick S.D., Maisonneuve I.M., Kitchen B.A., Fleck M.W. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 2002, 438(1-2):99-105.
88. Godfrey C., Cave J. Foresight state of science review-Economics of Addiction and Drugs 2005, Department of Trade and Industry, London.
89. Godfrey C., Eaton G., McDougall C., Culyer A. Home Office Research Study 249: The economic and social costs of Class A drug use in England and Wales, 2000 2002, Home Office, London.
90. Gonzales M., Nutt D.J. Gammahydroxybutyrate (GHB) abuse and dependency. J Psychopharmacol 2005, 19:219-220.
91. Gorelick D.A., Gardner E.L., Xi Z.X. Agents in development for management of cocaine abuse. Drugs 2004, 64(14):1547-1573.
92. Gossop M., Marsden J., Stewart D. The National Treatment Outcome Research Study: changes in substance use, health and criminal behaviour during the five years after intake 2001, National Addiction Centre, London.
93. Green A.R., O'Shea E., Colado M.I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004, 500(1-3):3-13.
94. Gyertyan I., Gal K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 2003, 14(1):93-98.
95. Hall W., Pacula R.L. Cannabis use and dependence: public health and public policy 2003, Cambridge University Press, Cambridge.
96. Halpern J.H., Pope H.G. Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug Alcohol Depend 2003, 69:109-119.
97. Harris B.R., Gibson D.A., Prendergast M.A., et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve crosstalk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res 2003, 27(11):1724-1735.
98. Hart C.L., Ward A.S., Collins E.D., Haney M., Foltin R.W. Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug Alcohol Depend 2004, 73(3):279-287.
99. Harvey D.M., Yasar S., Heishman S.J., Panlilio L.V., Henningfield J.E., Goldberg S.R. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology 2004, 175(2):134-142. Epub 2 march.
100. Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 2004, 172:145-156.
101. Hatsukami D.K., Lemmonds C., Tomar S.L. Smokeless tobacco use: harm reduction or induction approach?. Prev Med 2004, 38:309-317.
102. Henquet C., Krabbendam L., Spauwen J., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330(7481):11-15. Epub 1 December 2004.
103. Herraiz T., Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005, 326(2):378-386.
104. Hikida T., Kitabatake Y., Pastan I., Nakanishi S. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci USA 2003, 100(10):6169-6173. Epub 29 April.
105. HM Treasury Spending Review 2004: Public Service Agreements 2005-2008, Chapter 21 - Action against illegal drugs 2004, HM Treasury, London.
106. Hoaken P.N.S., Stewart S.H. Drugs of abuse and the elicitation of human aggressive behavior. Addictive Behaviors 2003, 28:1533-1554.
107. Holtzman S.G. Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine. Psychopharmacology 2001, 155(2):180-186.
108. Horgan J. The electric kool-aid clinical trial. New Scientist 2005, 185:36-39.
109. Huang Y.C., Wang S.J., Chiou L.C., Gean P.W. Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 2003, 23(32):10311-10320.
110. Hulse G.K., Arnold-Reed D.E., O'Neil G., Chan C.T., Hansson R., O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004, 9(1):59-65.
111. Hungund B.L., Szakall I., Adam A., Basavarajappa B.S., Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003, 84(4):698-704.
112. Hurwitz B Foresight state of science reviewlife histories and narratives of addiction 2005, Department of Trade and Industry, London.
113. Iversen L.L. The science of marijuana 2001, Oxford University Press, Oxford.
114. Iversen L. Cannabis and Ecstasy - soft drugs?. Proceedings of seminar I: Drugs and the brain 2002, Beckley Foundation, Oxford.
115. Iversen L. Cannabis and the brain. Brain 2003, 126(6):1252-1270.
116. Jacobsen L.K., Southwick S.M., Kosten T.R. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 2001, 158(8):1184-1190.
117. Johnson B.A., Roche J.D., Javors M.A. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000, 284(8):963-971.
118. Johnson B.A., Swift R.M., Ait-Daoud N., DiClemente C.C., Javors M.A., Malcolm R.J. Development of novel pharma-cotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 2004, 28(2):295-301.
119. Joseph Rowntree Foundation Drugs: dilemmas, choices, and the law 2000, Joseph Rowntree Foundation, London.
120. Marijuana and medicine 1999, Institute of Medicine, National Academy Press, Washington DC. J.E. Joy, J. Watson, J.A. Benson (Eds.).
121. June H.L., Foster K.L., McKay P.F., et al. The reinforcing properties of alcohol are mediated by GABA(A1) receptors in the ventral pallidum. Neuropsychopharmacology 2003, 28(12):2124-2137.
122. Kahlig K.M., Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine amphetamine, and cocaine. Eur J Pharmacol 2003, 479:153-158.
123. Kelly T.H., Stoops W.W., Perry A.S., Prendergast M.A., Rush C.R. Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures. Behav Cog Neurosci Rev 2003, 2(4):227-260.
124. Khanna J.M., Kalant H., Shah G., Chau A. Effect of D-cycloserine on rapid tolerance to ethanol. Pharmacol Biochem Behav 1993, 45(4):983-986.
125. Kiefer F., Wiedemann K. Combined therapy: what does acamprosate and naltrex-one combination tell us?. Alcohol Alcohol 2004, 39(6):542-547. Epub 29 September.
126. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharm Sci 1999, 20:19-26.
127. Kiritze-Topor P., Huas D., Rosenzweig C., Comte S., Paille F., Lehert P. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. Alcohol Alcohol 2004, 39(6):520-527. Epub 10 August.
128. Kollins S.H. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psych 2003, 64(Suppl II):14-18.
129. Kollins S.H., MacDonald E.K., Rush C.R. Assessing the abuse potential of methylphenidate in nonhuman and human subjects - a review. Pharm Biochem Behav 2001, 68:611-627.
130. Kosten T.R., Rosen M., Bond J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20:1196-1204.
131. Kranzler H.R. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000, 35(6):537-547.
132. Kushner S.A., Dewey S.L., Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 1999, 290(2):797-802.
133. Lader D., Meltzer H. Drinking: adults' behaviour and knowledge in 2002 2002, Office for National Statistics, London.
134. Lange J.H., Kruse C.G. Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Dev 2004, 7(4):498-506.
135. Laviolette S.R., Gallegos R.A., Henriksen S.J., van der Kooy D. Opiate state controls bi-directional reward signaling via GABAA receptors in the ventral tegmental area. Nat Neurosci 2004, 7(2):160-169. Epub 18 January.
136. Ledent C., Valverde O., Cossu G., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor, knockout mice. Science 1999, 283(5400):401-404.
137. Ledgerwood L., Richardson R., Cranney J. D-cycloserine and the facilitation of extinction of conditioned, fear: consequences for reinstatement. Behav neurosci 2004, 118(3):505-513.
138. Lee B., Tiefenbacher S., Platt D.M., Spealman R.D. Role of the hypothalamic-pituitary-adrenal axis in reinstatement of cocaine-seeking behavior in squirrel monkeys. Psychopharmacology 2003, 168(1-2):177-183. Epub 22 March.
139. Lee B., Tiefenbacher S., Platt D.M., Spealman R.D. Pharmacological, blockade of alpha2-adrenoceptors induces rein-statement of cocaine-seeking behavior in squirrel monkeys. Neuropsychopharmacology 2004, 29(4):686-693.
140. LeFoll B., Goldberg S.R. Cannabinoid CB1 antagonists, as promising new medications for drug dependence. J Pharmacol Exp Ther 2004, 3 November. Epub ahed of print.
141. Lelong V., Dauphin F., Boulouard M. RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology 2001, 41(4):517-522.
142. Lieb R., Schuetz C.D., Pfister C.H., von Sydow K., Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 2002, 68(2):195-207.
143. Liechti M.E., Vollenweider F.X. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 2000, 14(3):269-274.
144. Lindsey K.P., Wilcox K.M., Votaw J.R., et al. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther 2004, 309(3):959-969. Epub 24 February.
145. Lingford-Hughes A., Nutt D. Neurobiology of addiction and implications for treatment. Br J Psychiatry 2003, 182:97-100.
146. Lingford-Hughes A.R., Davies S.J., McIver S., Williams T.M., Daglish M.R., Nutt D.J. Addiction. Br Med Bull 2003, 65:209-222.
147. Lingford-Hughes A.R., Welch S., Nutt D.J. British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004, 18(3):293-335.
148. Loonam T.M., Noailles P.A.H., Yu J., Zhu J.P.Q., Angulo J.A. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum. Life Sci 2003, 73:727-739.
149. Lopes D.V.S., Caruso R.R.B., Castro N.G., Costa P.R.R., da Silva A.J.M., Noel F. Characterization of a new synthetic isoflavonoid with inverse agonist activity at the central benzodiazepine receptor. Eur J Pharmacol 2004, 495:87-96.
150. Lu L., Liu Z., Huang M., Zhang Z. Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes. J Neurochem 2003, 84(6):1378-1386.
151. Lyle J., Cadet J.L. Methylene-dioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Rev 2003, 42:155-168.
152. MacLeod J., Oakes R., Copello A., et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
153. Mailliard W.S., Diamond I. Recent advances in the neurobiology of alcoholism: the role of adenosine. Pharm Ther 2004, 101:39-46.
154. Maisonneuve I.M., Glick S.D. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 2003, 75(3):607-618.
155. Maldonado R., Fonseca R. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002, 22:1326-1331.
156. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004, 28(1):51-63.
157. Marsicano G., Wotjak C.T., Azad S.C., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
158. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000, 12(11):4038-4046.
159. Matsumoto R.R., Liu Y., Lerner M., Howard E.W., Brackett D.J. Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 2003, 469(1-3):1-12.
160. Maurice T., Martin-Fardon R., Romieu P., Matsumoto R.R. Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002, 26(4):499-527.
161. McCann U.D., Ricaurte G.A. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 2004, 27:821-826.
162. McDonough M., Kennedy N., Glasper A., Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004, 75:3-9.
163. McKeganey N. Foresight state of science review-sociology 2005, Department of Trade and Industry, London.
164. Meis S. Nociceptin/orphanin FQ: actions within the brain. Neuroscientist 2003, 9(2):158-168. doi: 10.1177/1073858403252231.
165. Mendelson W.B., Roth T., Cassella J., et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004, 8:7-17. (1).
166. Meyer R.E. The disease called addiction: emerging evidence in a 200-year debate. Lancet 1996, 347:162-166.
167. Milivojevic N., Krisch I., Sket D., Zivin M. The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rat. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(6):576-582. Epub 7 May.
168. Modesto-Lowe V. Naltrexone depot (Drug Abuse Sciences). IDrugs 2002, 5(8):835-838.
169. Morris K. Ecstasy users face consequences of neurotoxicity. Lancet 1998, 352:1911.
170. Morris K. Research reawakens ecstasy neurotoxicity debate. Lancet Neurology 2003, 2:650.
171. Morris K. Melanocortins key to trigger sex on the brain. Lancet Neurology 2003, 2:140.
172. Morris K. Rat studies of Ritalin emphasise need for proper ADHD diagnosis. Lancet Neurol 2004, 3:75.
173. Morris K.A., Jones R., Nutt D.J. Foresight state of science review-cognition enhancers 2005, Department of Trade and Industry, London.
174. Morris P., Jones T., Lingford-Hughes A. Foresight state of science review-Neuroimaging 2005, Department of Trade and Industry, London.
175. Mukherjee R.A.S., Hollins S., Abou-Saleh M.T., Turk J. Low level alcohol consumption and the fetus. BMJ 2005, 330:375-376. doi:10.1136/bmj.330.7488.375.
176. Murtra P., Sheasby A.M., Hunt S.P., De Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance, P. Nature 2000, 405:180-183.
177. Myrick H., Henderson S., Brady K.T., Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry 2001, 62(1):19-23.
178. Nagy J. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism?. IDrugs 2004, 7(4):339-350.
179. Nagy J., Horvath C., Farkas S., Kolok S., Szombathelyi Z. NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. Neurochem Int 2004, 44(1):17-23.
180. Nestler E.J. New treatments for drug addiction: intracellular targets for drug discovery. Neuropsychopharmacology 2004, (Suppl 1):S60. (ACNP annual meeting).
181. Nicholls D. Hallucinogens. Pharm Ther 2004, 101:131-181.
182. Nie Z., Schweitzer P., Roberts A.J., Madamba S.G., Moore S.D., Siggins G.R. Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors. Science 2004, 303:1512-1514.
183. Nitsche M.A., Jaussi W., Liebetanz D., Lang N., Tergau F., Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology 2004, 29(8):1573-1578.
184. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsych Clin Neurosci 2003, 15:317-325.
185. Nowak R. How our brains fend off madness. New Scientist 2004, 184:13.
186. Nutt D. Addiction: processes of change 1994, Oxford Medical Publications, Oxford. G. Edwards, M. Lader (Eds.).
187. Nutt D. Alcohol and the brain: pharmacological insights for psychiatrists. Br J Psych 1999, 175:114-119.
188. Nutt D. Heroin and related opiates. Proceedings of seminar I: Drugs and the brain 2002, Beckley Foundation, Oxford.
189. Nutt D.J. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 2003, 17(4):355-364.
190. Nutt D. Alcohol and the brain. Proceedings of seminar III: Alcohol and other recreational drugs 2003, Beckley Foundation, Oxford.
191. Nutt D. Cannabis antagonists: a new era of social psychopharmacology?. J Psychopharmacol 2005, 19:3-4.
192. Nutt D.J., Malizia A.L. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001, 179:390-396.
193. Nutt D., Lingford-Hughes A., Dalglish M. Future directions in substance dependence research. J Neural Transm 2003, 64(Suppl):95-103.
194. O'Shea E., Escobedo I., Orio L., et al. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 2005, Jan 26. Epub ahead of print.
195. Office for National Statistics Results from the General Household Survey 2003/4 2004, Office for National Statistics, London.
196. Office for National Statistics Deaths related to drug poisoning: England and Wales, 1999-2003. Health Statistics Quarterly 2005, 25:52-59.
197. Oldham N.S., Wright N.M., Adams C.E., Sheard L., Tompkins C.N. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project: an open-label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for primary care detoxification from either street heroin or methadone. BMC Fam Pract 2004, 5(1):9.
198. Oliveto A., Benios T., Gonsai K., Feingold A., Poling J., Kosten T.R. D-cycloserine-naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. Exp Clin Psychopharmacol 2003, 11(3):237-246.
199. Orford J. The psychopharmacology of addiction 1988, Oxford Medical Publications, Oxford. M. Lader (Ed.).
200. Orford J. Foresight state of science review-problem gambling and other behavioural addictions 2005, Department of Trade and Industry, London.
201. Osselton D., Cowan D., Robinson S. Foresight state of science review-drug testing 2005, Department of Trade and Industry, London.
202. Oswald L.M., Wand G.S. Opioids and alcoholism. Phys Behav 2004, 81:339-358.
203. Patkar A.A., Gottheil E., Berrettini W.H., Hill K.P., Thornton C.C., Weinstein S.P. Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression, and craving among African-American cocaine abusers. Am J Addict 2003, 12(5):432-447.
204. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002, 325(7374):1195-1198.
205. Paul M., Dewey S.L., Gardner E.L., Brodie J.D., Ashby C.R. Gamma-vinyl, GABA(GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse 2001, 41(3):219-220.
206. Pembrey M., Ball D., Stephens D. Foresight state of science review - genomics 2005, Department of Trade and Industry, London.
207. Phillips H., Lawton G. The intoxication instinct. New Scientist 2004, 184:32-41.
208. Pietraszek M. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pol J Pharmacol 2003, 55:133-154.
209. Pistis M., Perra S., Pillolla G., Melis M., Muntoni A.L., Gessa G.L. Adolescent exposure to cannabinoids induces longlasting changes in the response to drug of abuse of rat midbrain dopamine neurons. Biol Psychiatry 15 July 2004, 56(2):86-94.
210. Popp R.L., Lovinger D.M. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 2000, 394(2-3):221-231.
211. Pouletty P. Drug addictions as treatable diseases. Euro Biotech News 2004, 3(5):44-46.
212. Prime Minister's Strategy Unit Alcohol harm reduction strategy for England 2004, Strategy Unit, London.
213. Putnins A. Substance use and the prediction of young offender recidivism. Drug Alcohol Rev 2003, 22(4):401-408.
214. Raby W.N., Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry 2004, 65(1):84-86.
215. Racz I., Bilkei-Gorzo A., Toth Z.E., Michel K., Palkovits M., Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 2003, 23(6):2453-2458.
216. Ranaldi R., Poeggel K. Baclofen decreases methamphetamine self-administration in rats. Neuroreport 2002, 13(9):1107.
217. Reneman L. Designer drugs: how dangerous are they?. J Neural Transm 2003, 66(Suppl):61-83.
218. Rezvani A.H., Overstreet D.H., Perfumi M., Massi M. Plant derivatives in the treatment of alcohol dependency. Pharmacol Biochem Behav 2003, 75(3):593-606.
219. Robbins T.W., Cardinal R., Everitt B. Foresight state of science review-neuroscience 2005, Department of Trade and Industry, London.
220. Roberts D.C., Andrews M.M. Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology 1997, 131(3):271-277.
221. Rocha B.A. Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. Eur J Pharmacol 2003, 479(1-3):107-115.
222. Roddy E. Bupropion and other non-nicotinic pharmacotherapies. BMJ 2004, 328:509-511. Epub 18 October. doi:10.1136/bmj.328.7438.509.
223. Rodriguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276(5321):2050-2054.
224. Romberger D.J., Grant K. Alcohol consumption and smoking status: the role of smoking cessation. Biomed Pharmacotherapy 2004, 58:77-83.
225. Room R. Foresight state of science review-social policy 2005, Department of Trade and Industry, London.
226. Russo-Neustadt A. Brain-derived neurotrophic factor, behavior, and new directions for the treatment of mental disorders. Semin Clin Neuropsychiatry 2003, 8(2):109-118.
227. Saadat K.S., O'Shea E., Colado M.I., Elliott J.M., Green A.R. The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ('ecstasy') when housed at high ambient temperature. Psychopharmacology 2005, Epub ahead of print.
228. Sahakian B., Turner D., Duka T. Foresight state of science review-experimental psychology 2005, Department of Trade and Industry, London.
229. Sakai J.T., Hall S.K., Mikulich-Gilbertson S.K., Crowley T.J. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J Am Acad Child Adolesc Psychiatry 2004, 43(9):1080-1088.
230. Sanchez V., O'Shea E., Saadat K.S., Elliott J.M., Colado M.I., Green A.R. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. J Psychopharmacol 2004, 18(3):412-416.
231. Schifano F., Oyefeso A., Webb L., Pollar M., Corkery J., Ghodse A.H. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. BMJ 2003, 326:80-81.
232. Schroeder J.P., Iller K.A., Hodge C.W. Neuropeptide-Y Y5 receptors modulate the onset and maintenance of operant ethanol self-administration. Alcohol Clin Exp Res 2003, 27(12):1912-1920.
233. Schultz W. Reward signaling by dopamine neurons. Neuroscience 2001, 7:293-302.
234. Sheffler D.J., Roth B.L. Salvinorin A: the 'magic mint' hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharm Sci 2003, 24:107-109.
235. Shepard J.D., Bossert J.M., Liu S.Y., Shaham Y. The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 2004, 55(11):1082-1089.
236. Shoptaw S., Yang X., Rotheram-Fuller E.J., et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003, 64(12):1440-1448.
237. Shpilenya L.S., Muzychenko A.P., Gasbarrini G., Addolorato G. Metadoxine in acute alcohol intoxication; a double-blind, randomized, placebo-controlled study. Alcohol Clin Exp Res 2002, 26:340-346.
238. Shulgin S. Studying consciousness. Exploring Consciousness conference 2004.
239. Shulgin S., Shulgin A. PIHKAL: a chemical love story 1991, Transform Press, Berkeley, California.
240. Shulgin S., Shulgin A. TIHKAL: the continuation 1997, Transform Press, Berkeley, California.
241. Simantov R. Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sciences 2004, 24:803-814.
242. Sinha R., Talih M., Malison R., Cooney N., Anderson G.M., Kreek M.J. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology 2003, 170(1):62-72. Epub 4 July.
243. Smit F., Bolier L., Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004, 99:425-430.
244. Snyder S. Forty years of neurotransmitters: a personal account. Arch Gen Psych 2002, 59:983-994.
245. Sobel B.F., Sigmon S.C., Walsh S.L., et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 2004, 73(1):11-22.
246. Solinas M., Panlilio L.V., Antoniou K., Pappas L.A., Goldberg S.R. The cannabinoid CB1 antagonist N-piperidinyl-5- (4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 2003, 306(1):93-102. Epub 26 March.
247. Soyka M., Chick J. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective. Am J Addict 2003, 12(Suppl 1):S69-S80.
248. Stinus L., Cador M., Zorrilla E.P., Koob G.F. Buprenorphine and a CRF(1) antagonist block the acquisition of opiate withdrawalinduced conditioned place aversion in rats. Neuropsychopharmacology 12 May 2004, Epub ahead of print.
249. Stromberg M.F., Mackler S.A., Volpicelli J.R., O'Brien C.P., Dewey S.L. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav 2001, 68(2):291-299.
250. Sumnall H.R., Wagstaff G.F., Cole J.C. Self-reported psychopathology in polydrug users. J Psychopharmacology 2004, 18(1):75-82.
251. Swift W., Hall W., Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Drug Alcohol Depend 2001, 63(2):147-153.
252. Szekeres H.J., Atack J.R., Chambers M.S., et al. 3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of a5-containing GABAA receptors. Bioorganic Med Chem Lett 2004, 14:2871-2875.
253. Tomar S.L., Connolly G.N., Wilkenfeld J., Henningfield J.E. Declining smoking in Sweden: is Swedish Match getting the credit for Swedish tobacco control's efforts?. Tob Control 2003, 12:368-371.
254. Twigg L., Moon G., Walker S. The smoking epidemic in England 2004, Health Development Agency, London.
255. Valdez G.R., Sabino V., Koob G.F. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 2004, 28(6):865-872.
256. Valdez G.R., Zorrilla E.P., Roberts A.J., Koob G.F. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 2003, 29(2):55-60.
257. van der Stelt M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003, 480(1-3):133-150.
258. Verdoux H., Tournier M. Cannabis use and risk of psychosis: an etiological link?. Epidemiol Psychiatr Soc 2004, 13(2):113-119.
259. Vetulani J. Drug addiction. Part III: Pharmacotherapy of addiction. Pol J Pharmacol 2001, 53:415-434.
260. Volkow N.D., Fowler J.S., Wang G.J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999, 13:337-345.
261. Vollenweider F.X., Liechti M.E. Acute psychological and physiological effects of MDMA ('Ecstasy') after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 2000, 10:289-295.
262. Vorel S.R., Ashby C.R., Paul M., et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002, 22(21):9595-9603.
263. Walker D.L., Ressler K.J., Lu K.T., Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002, 22(6):2343-2351.
264. Walker D.D., Venner K., Hill D.E., Meyers R.J., Miller W.R. A comparison of alcohol and drug disorders: is there evidence for a developmental sequence of drug abuse?. Addict Behav 2004, 29(4):817-823.
265. Waszkielewicz A., Bojarski J. <>-hydroxybutyric acid (GHB) and its chemical modifications: a review of the GHBergic system. Pol J Pharmacol 2004, 56:43-49.
266. Weiss F., Ciccocioppo R., Parsons L.H., Katner S., Liu X., Zorrilla E.P., Valdez G.R., Ben-Shahar O., Angeletti S., Richter R.R. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann NY Acad Sci 2001, 937:1-26.
267. Wichniak A., Brunner H., Ising M., Pedrosa Gil F., Holsboer F., Friess E. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression. Psychoneuroendocrinology 2004, 29(9):1101-1108.
268. Wilens T.E. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, who is at risk, and treatment issues. Primary Psychiatry 2001, 11(7):63-70.
269. Williams K., Wu T., Colangelo C., Nairn A.C. Recent advances in neuroproteomics and potential application to studies of drug addiction. Neuropharmacol 2004, 47:148-166.
270. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
271. Wingerchuck G. Cannabis for medical purposes: cultivating science, weeding out the fiction. Lancet 2004, 264:315-316.
272. Wlaz P. Anti-convulsant and adverse effects of the glycineB receptor ligans, D-cycloserine and L-701,324: comparison with competitive and non-competitive N-methyl-D aspartate receptor antagonists. Brain Res Bull Aug 1998, 46(6):535-540.
273. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998, 54(6):679-720.
274. Wong C.G.T., Gibson K.M., Snead O.C. From the street to the brain: neurobiology of the recreational drug <>-hydroxybutyric acid. Trends Pharm Sci 2004, 25(1):29-34.
275. World Health Organization International classification of diseases 1992, WHO, Geneva. 10th edition.
276. Xu M., Zhang J. Molecular genetic probing of dopamine receptors in drug addiction. Curr Opin Drug Discov Devel 2004, 7(5):703-708.
277. Xu G.P., Van Bockstaele E., Reyes B., Bethea T., Valentino R.J. Chronic morphine sensitizes the brain norepinephrine system to corticotropin-releasing factor and stress. J Neurosci 2004, 24(38):8193-8197.
278. Zachariou V., Brunzell D.H., Hawes J., et al. The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proc Natl Acad Sci USA 2003, 100(15):9028-9033. Epub 9 July.
279. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003, 69:215-232.
280. Zarrindast M.R., Faraji N., Rostami P., Sahraei H., Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav 2003, 74(2):363-369.
281. Zhu H., Jenab S., Jones K.L., Inturrisi C.E. The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat. Brain Res Dev Brain Res 2003, 142(2):209-213.
282. Miller R.L. The encyclopedia of addictive drugs 2002, Greenwood Press, Westport. http://www.wired.com.